From GlobeNewswire: 2025-03-19 02:00:00

Biotalys, an AgTech company, has made significant progress in 2024, with its first candidate biofungicide EVOCA™ recommended for EU approval. The company closed a €15 million private placement and has a solid financial runway until May 2026. Biotalys is working on advancing its product pipeline with promising results from field trials for BioFun-6.

In 2024, Biotalys made strides in regulatory reviews with the EPA and CTGB for EVOCA™, leading to promising developments in the European market. The company also secured patents for EVOCA™ in multiple regions and initiated field trials for BioFun-6, showing increased potency. Additionally, Biotalys introduced a new biofungicide program, BioFun-8, targeting a global market opportunity of approximately USD 1.1 billion.

Biotalys achieved operational and leadership milestones in 2024, including a successful private placement and the addition of key personnel to drive strategic partnerships and commercialization efforts. The company was recognized for its sustainable crop protection efforts, earning accolades as the Sustainable Crop Protection Company of the Year and making it to the FoodTech 500 list.

Looking ahead to 2025, Biotalys will focus on regulatory processes for EVOCA™ and EVOCA NG, expanding field trials for BioFun-6, and advancing its pipeline programs. With a strong financial position, the company aims to continue its innovative approach to sustainable crop protection.

Biotalys’ financial review for 2024 reflects a reduction in operating expenses, a solid cash balance of €22.6 million, and a strategic approach to financial management. The company’s consolidated financial statements are prepared in accordance with IFRS, and the auditor has confirmed the accuracy of the financial information.

Biotalys will publish its annual report on 21 March 2025 and hold its Annual General Shareholders Meeting on 22 April 2025. The company remains committed to transparency and communication with investors, hosting a live webcast and conference call to discuss its 2024 financial results and business highlights.



Read more at GlobeNewswire:: Biotalys Reports Full-Year 2024 Financial Results and